Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. (NASDAQ: FEMY) generates frequent news flow as a biomedical company focused on women’s reproductive health, fertility treatment and non-surgical permanent birth control. News updates commonly highlight progress across its product portfolio, including FemaSeed Intratubal Insemination, FemVue and FemVue Controlled diagnostic devices, FemBloc permanent birth control, and the FemChec diagnostic product.
Investors following FEMY news can expect coverage of regulatory milestones, such as U.S. FDA 510(k) clearance for FemVue Controlled and Investigational Device Exemption approval to advance the final phase of the FINALE pivotal trial for FemBloc. Company announcements also report international approvals for FemBloc in Europe, the UK and New Zealand, as well as the launch of post-market surveillance studies under EU Medical Device Regulation.
Femasys news releases frequently describe commercialization developments, including partnerships with distributors like Kebomed to expand FemBloc access in France and the Benelux region, initial commercial orders in European markets, and collaborations with healthcare providers such as Refuah Health Center to offer FemaSeed as a first-line infertility treatment in community-based care. Financial and capital markets updates, including quarterly results, underwritten offerings, and private placements of senior secured convertible notes and warrants, are also disclosed through press releases and related SEC filings.
This FEMY news page aggregates these updates in one place, making it easier to track clinical progress, regulatory events, commercialization agreements, and listing-related notices from Nasdaq. Readers can use this feed to review how Femasys is executing on its women’s health strategy and how new information may relate to the company’s fertility and permanent birth control portfolio over time.
Femasys Inc. (NASDAQ: FEMY) has been invited to present at the Women’s Health Panel Discussion hosted by Maxim Group LLC on July 13, 2022, at 11:00 a.m. ET. Kathy Lee-Sepsick, CEO, will discuss the implications of the Supreme Court's decision to overturn Roe v. Wade on women's health and contraception. This virtual event will spotlight the critical issues in women's reproductive health, bringing together key industry players. Femasys is known for its innovations in minimally invasive reproductive health technologies, including FemBloc and FemaSeed.
Femasys Inc. (NASDAQ: FEMY) announced the appointment of Charles Larsen as the new non-executive Chair of the Board, succeeding founder Kathy Lee-Sepsick. With over 40 years in the medical device industry, Larsen is expected to enhance corporate governance and aid Femasys in advancing its product candidates like FemBloc and FemaSeed. Kathy Lee-Sepsick emphasized Larsen's leadership experience and insight in strategic transformations as vital for the company's mission to improve women's health globally.
Femasys Inc. (NASDAQ: FEMY) announced that its CEO, Kathy Lee-Sepsick, will present at the LSX World Congress USA in Boston from June 21-22, 2022. She will lead a session on overcoming regulatory hurdles for women’s health products, focusing on FemaSeed and FemBloc. The Women’s Health CEO Forum will also feature her insights on industry collaboration. This event gathers leaders in biotech and medtech to drive innovation and growth in women's reproductive health.
Femasys Inc. (NASDAQ: FEMY) announced Q1 2022 financial results, reporting a net loss of $2.88 million or $0.24 per share. General and administrative expenses rose by 62.3% to $1.45 million, and R&D expenses increased by 42.8% to $1.42 million. Sales of FemVue® decreased by 2.5% to $321,405. Despite these challenges, Femasys is set to commercialize FemCerv® and FemCath™ by year-end and is making progress in clinical trials for FemBloc and FemaSeed. The company aims to enhance women's health solutions with its expanding product portfolio.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, will participate in the 2022 Virtual Growth Conference from March 28-30. CEO Kathy Lee-Sepsick will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 from 3:00 pm to 4:30 pm ET. The conference will discuss innovations in women's health, highlighting Femasys's ongoing development of minimally invasive technologies, including FemBloc® and FemaSeed® for permanent birth control and infertility treatment respectively. For more details, registration is available online.
Femasys Inc. (NASDAQ: FEMY) reported its 2021 financial results, showcasing a revenue increase of 13.7% to $1.18 million from FemVue® sales. R&D expenses slightly decreased by 1.1% to $4.08 million, while G&A expenses surged by 67.5% to $4.26 million due to increased professional costs. The net loss was $7.54 million, equating to $1.12 per share, a rise from the previous year's loss of $6.91 million. The company anticipates significant clinical advancements, including the upcoming launch of FemCerv® and completion of the FemBloc study enrollment.
Femasys Inc. (NASDAQ: FEMY) has appointed Dov Elefant as Chief Financial Officer, effective February 28, 2022. With 25 years of experience in financial management in the biotech sector, Elefant's expertise includes fundraising and mergers and acquisitions. He aims to enhance Femasys' growth and strategic direction in women's health technologies, including their lead products, FemBloc® and FemaSeed®. Additionally, an inducement option has been granted for 100,000 shares to Elefant, vesting over four years. This leadership change is expected to strengthen the company's financial strategy.
Femasys Inc. (NASDAQ: FEMY) has appointed Wendy Perrow to its board of directors, bringing extensive experience in fundraising and corporate strategy. Perrow's background includes leadership roles in several biotechnology companies, notably raising $31 million for Alba Therapeutics. This announcement coincides with the resignation of William Witte, who served since 2017. The leadership change comes at a crucial time as Femasys prepares for pivotal trials for its product candidates FemBloc and FemaSeed. Perrow aims to leverage her expertise to enhance the company's growth in women's reproductive health.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, announced its participation in two upcoming virtual conferences. The LifeSci Partners 11th Annual Corporate Access Event will feature CEO Kathy Lee-Sepsick on January 6, 2022, discussing gender equality in life sciences. Additionally, Femasys will present at the H.C. Wainwright BioConnect Conference, with a recording available from January 10, 2022. Femasys develops minimally invasive technologies, including FemBloc® and FemaSeed® for reproductive health needs.
Femasys Inc. (NASDAQ: FEMY) has received investigational device exemption approval for its pivotal LOCAL trial involving FemaSeed®, aimed at improving women's reproductive health. The company reported third-quarter 2021 financial results, highlighting a net loss of $(2.26) million, with revenue from FemVue® declining by 13.9% year-over-year to $269,581. However, sales increased by 22.2% for the nine months ended September 30, 2021, totaling $925,362. The company also announced its addition to the Russell Microcap® Index and the appointment of a new chief medical officer.